Member Info for AgentB

This sounds highly significant. The Gov can expect to take the flack for a while from Deeks et al for misusing the unreliable Innova test and pivoting away from the global gold standard PCR test, not to mention the new quarantine at own expense regulations, but this is perhaps Boris’s ‘Darkest Hour’. The narrative is heading towards Moonshot.

And where absolutely forced to comment, the need for a bit of waffle to protect secrecy.

Their website doesn’t give much away... apart from the fact that there are a load more reagents out there than I had ever heard of! https://www.lateraldx.com/services/reagent-supply.html

Exactly. It’s news quality, not quantity that counts. At the moment, no news is supportive of the big sovereign push narrative.

Well he did bugger off to Singapore!

During WWII, my Grandad, an automotive engineer at Ford, was required to repurpose machines to build Spitfire components. I think these companies would love to be involved in another meaningful sovereign effort.

Why are we limiting our horizons to the capacity of BBI, Abingdon and ODX? Take a look at this 2.5 minute video from PA consulting about how they coordinated the ventilator challenge earlier in the pandemic. Note the experience and relationships that they have in place as a result.
https://youtu.be/4ZcVCmGE-dw (We’re talking Ford, Rolls Royce etc, a real war time effort.)

M&A activity.
FTI Consulting was named as the leading PR Advisor to M&A deals in the UK in 2017, according to research by Mergermarket.

FTI Consulting Recognised as Leading PR Advisors to M&A Transactions by Volume (Spain)

Why on earth would they produce a test that wasn’t even approved by its own regulators?
https://thedeepdive.ca/sona-nanotech-withdraws-health-canada-application-for-covid-19-test-due-to-feedback-from-regulator/

Indeed. Moonshot will happen, and it will be HUGE and Avacta will be central to it. All I’m suggesting is that the Gov would be shooting itself in the foot to announce it too early.

But if testing becomes a viable ALTERNATIVE to vaccination, this along with mounting concerns about vaccine efficacy, could decrease vaccine acceptance rate below the level required for herd immunity. I just think that until as much vaccination as possible has been done, there is an incentive for Gov to keep quiet about testing advances.

I totally agree. I’m just talking about communication. If the Gov relaunches Moonshot worth a big fanfare and super sensitive test, people will refuse the vaccine because there is another escape route.

I think that we are far more sensitive to stories about the failings of the various vaccines than the general public though. As far as they are concerned, it is still their best hope, and I believe the Gov will want them to think that way for as long as possible.
The other possibility is that the public pressure regarding schools reopening grows to the point of mutiny. Many parents are going mad being cooped up with their school-age children. This is the balance for the Gov to weigh in terms of communications.
Meanwhile, what can AS say or do to keep us relaxed? Not a lot I fear.

Just a thought here, but if the Gov wants maximum uptake of the vaccine, and they are in charge of the timing of the announcement of any alternative routes out of the crisis, isn’t this an incentive for them to keep a lid on the news of a sovereign test for as long as possible?
It seems that the advent of the ‘Kent variant’ and the constant hyping of the vaccine roll-out as being our route out of lockdown has resulted in over 80% of the population being willing to take the jab, enough to achieve herd immunity. My suspicion is that the Gov will therefore continue to keep promoting the vaccination program for as long as possible before announcing the resumption of ‘Moonshot’ featuring a much more robust, British developed test.
I therefore fear a few weeks more of silence. If all Avacta’s communication is covered by ‘Sovereign test’ NDA, we are completely at the mercy of the Gov regarding timing of any positive RNS. What do others think?

https://apple.news/AKb_tauUXQaqfj9ieP3yTUQ
The only story I can find suggests that they are still pretty keen on taking delivery. Can’t find comicstar’s reference.

I’m fed up of being in shares where the MMs manipulate the price to fulfil insti orders at low prices. You can tell when they are doing it because the share price stays within a narrow range and any rises on good news or sentiment are swiftly dampened down. Did you see what they did with the spread on Friday when we were motoring?

Just a reminder that the investment and life sciences industry experts view AS as a clear communicator, not a waffles, and Avacta as having plenty of performance potential beyond Covid tests.

https://www.lse.co.uk/media/hardman-healthcare-index-life-sciences-where-the-smart-money-was-in-an-exceptional-2020.html (From 15 minutes)

Donald Leggatt (Interviewer from LSE): Give me a couple of small cap winners which will continue to outperform [in 2021]. I mean, I’m thinking Avacta. What do you think?

Dr Martin Hall (Head of life sciences at Hardman & Co.): Well you put the words in my mouth!

DL: I just think Alastair Smith is a good chap.

Dr Hall: Alastair is a) a really good CEO but also b) I like the way he is able to explain what is potentially difficult technology in a very straightforward and understandable way. But what I particularly like about Avacta is that it’s got three approaches: it’s got big partners for the pandemic aspect (which is all add-on, it wasn’t there a year ago and it is today); it is continuing to attract licensing partners for the Affimer technology and, thirdly, (and this is where I liken Avacta to being a mini/next generation Abcam, I think the approach and everything is exactly the same but the business model is somewhat different) Avacta is also developing its own therapeutics, using its Affimer technology and it should enter the clinic with its first therapeutic in 2021, and that is usually associated with a value enhancement point.

I hope we pay them on the basis of results.

Yes, compared with ABDX also, they are certainly getting more attention.

Thanks to the sterling efforts of Yellow Jersey PR, we still seem to be flying under the radar.